# Ketamine Biomarker Validation

> **NCT07307768** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Soterix Medical** · enrollment: 20 (estimated)

## Conditions studied

- Treatment Resistant Depression (TRD)

## Interventions

- **DRUG:** Ketamine (0.25 mg/kg)
- **DRUG:** Ketamine (0.5 mg/kg)
- **DRUG:** Ketamine (0.75 mg/kg)

## Key facts

- **NCT ID:** NCT07307768
- **Lead sponsor:** Soterix Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07307768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07307768, "Ketamine Biomarker Validation". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07307768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*